DLH Holdings Corp. — FY2015 Form 10-K
Reporting period: Fiscal year ended September 30, 2015. The filing also reports unaudited fourth-quarter results; it is an annual report, not a standalone Q4 filing. DLH provides healthcare and logistics services to U.S. government agencies, primarily through its wholly owned subsidiary.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $65.3 million | $60.5 million |
| Gross margin | $11.7 million; 17.9% | $9.0 million; 14.8% |
| Operating income | $2.5 million; 3.8% of revenue | $0.8 million; 1.3% |
| Income before tax | $3.2 million | $0.8 million |
| Net income | $8.7 million; diluted EPS $0.87 | $5.4 million; diluted EPS $0.54 |
| Adjusted EBITDA (non-GAAP) | $3.0 million | $1.3 million |
| Cash from operations | $2.0 million | $1.7 million |
Revenue increased 8.0%. Gross margin improved primarily from stronger contract performance, a more favorable contract mix, productivity initiatives, and cost management. G&A rose 13.0% to $9.1 million, reflecting higher business volume and investment in business development and proposals.
Net income included a $5.5 million deferred tax benefit from releasing part of the valuation allowance; FY2014 included a $4.6 million benefit. Thus, reported net income and EPS substantially reflect non-cash tax benefits, rather than operating earnings alone. Annual other income, net, was $0.7 million, including the legacy payroll-tax resolution and the retroactive-payment settlement.
At September 30, 2015, cash was $5.6 million, working capital was $4.6 million, total liabilities were $5.8 million, and the balance sheet showed no outstanding loan balance. The asset-based credit facility had approximately $1.29 million of unused loan capacity, subject to eligible receivables, plus a $1.35 million letter-of-credit reserve. Management said cash, available credit, planned operating cash flow, and cost controls should support operations for 12 months from the financial-statement date.
Backlog was approximately $146 million, down from $184 million a year earlier: $50 million funded and $96 million unfunded. Backlog includes estimates and options and is not assured revenue. No specific company revenue or earnings guidance is provided.
In Q4 FY2015, revenue was $17.0 million, gross margin $3.4 million, operating income $1.0 million, and net income $8.2 million. The quarter included a $5.8 million income-tax benefit and $1.5 million of other income, so quarterly net income was unusually elevated.
Material developments, outlook, and risks
- The Department of Veterans Affairs accounted for approximately 95% of FY2015 revenue, down from 96%; all revenue came directly or indirectly from the U.S. government. This customer and funding concentration is a major exposure.
- DLH expanded revenue through new awards and current-program growth and reported a 10.5% two-year revenue CAGR from FY2013 to FY2015. It highlighted healthcare delivery and logistics, including expansion into DoD and other federal agencies, as growth priorities.
- The VA Consolidated Mail Order Pharmacy healthcare contract was expected to run through October 2016 and be recompeted for a new term; the company intended to pursue renewal. Other cited contract vehicles had stated terms into 2017 and 2018.
- Management pointed to proposed federal health spending and the 2015 bipartisan budget agreement as supportive trends, while noting that FY2016 appropriations remained pending under a continuing resolution. No assurance was given that budget levels, contract awards, or options would translate into DLH revenue.
- In September 2015, the IRS confirmed that no taxes, interest, or penalties were due on a legacy payroll-tax matter. This produced approximately $1.5 million of favorable other income. Separately, a DVA retroactive-payment matter was resolved by mutual release; the company removed $9.3 million of receivables and $8.7 million of accrued payroll liabilities and recorded a $629,000 non-cash net charge.
- Key risks include VA dependence and contract recompetes, federal appropriations and shutdown delays, competitive bidding and protests, contract termination or non-renewal, personnel and compliance risks, and possible impairment of $8.6 million of goodwill. The company reported no material litigation known to management and no goodwill impairment for FY2015.
Investor verification priorities
- Verify the composition and repeatability of earnings, particularly the valuation-allowance tax benefit and the payroll-tax and retroactive-claim items.
- Check the status, recompete timing, and renewal outcome of the VA pharmacy healthcare contract, and the company’s progress diversifying beyond the VA.
- Assess funded versus unfunded backlog, contract options, customer funding, and whether backlog converts into revenue and cash flow.
- Review available borrowing capacity and credit-facility terms, including eligibility limits, renewal, and covenants.
- Monitor gross-margin performance, working-capital and receivables trends, and the potential sensitivity of goodwill to contract losses.